Oncology Research Program

Restricted access
Highlights of the NCCN Oncology Research Program The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts. NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian, or Primary Peritoneal Cancer Principal Investigator: Marcela G. del Carmen, MD, MPH Condition: Ovarian cancer; fallopian tube cancer; peritoneal cancer Institutions: Massachusetts Hospital, Dana Farber Cancer Institute Each study cycle will last 28 days. On day 1, participants will receive carboplatin intravenously. On days 1 and 15 of each cycle, they will receive pralatrexate intravenously. Participants will also be asked to take folic acid orally daily starting 7 days before the first dose of pralatrexate and continuing until 30 days after the last dose of pralatrexate. They will receive a vitamin B12 injection no more than 10 weeks before the first dose of pralatrexate and every 8 to 10 weeks...

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 13 7 4
PDF Downloads 1 1 0
EPUB Downloads 0 0 0